特异性药物诱导的肝损伤模拟急性和慢性肝病。由于缺乏病理学诊断血清学标志物,因此尚未得到认可和认可。其后果可能从无症状到自限性疾病到严重的肝损伤导致急性肝功能衰竭。它的发病率在亚洲可能比世界其他地区更常见,主要是因为结核病治疗引起的肝毒性以及亚洲国家普遍使用传统和免费药物。本APASL关于DILI的共识指南简要介绍了各个方面,包括有关DILI的当前基于证据的信息,特别是由于亚洲的抗结核药以及传统和补充药物的使用而引起的DILI。
Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.